Clinical Pharmacokinetics

, Volume 53, Issue 8, pp 659–678 | Cite as

Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved

Current Opinion

Abstract

Hepatobiliary transport mechanisms have been identified to play a significant role in determining the systemic clearance for a number of widely prescribed drugs and an increasing number of new molecular entities (NMEs). While determining the pharmacokinetics, drug transporters also regulate the target tissue exposure and play a key role in regulating the pharmacological and/or toxicological responses. Consequently, it is of great relevance in drug discovery and development to assess hepatic transporter activity in regard to pharmacokinetic and dose predictions and to evaluate pharmacokinetic variability associated with drug–drug interactions (DDIs) and genetic variants. Mechanistic predictions utilizing physiological-based pharmacokinetic modeling are increasingly used to evaluate transporter contribution and delineate the transporter–enzyme interplay on the basis of hypothesis-driven functional in vitro findings. Significant strides were made in the development of in vitro techniques to facilitate characterization of hepatobiliary transport. However, challenges exist in the quantitative in vitro–in vivo extrapolation of transporter kinetics due to the lack of information on absolute abundance of the transporter in both in vitro and in vivo situations, and/or differential function in the holistic in vitro reagents such as suspended and plated hepatocytes systems, and lack of complete mechanistic understanding of liver model structure. On the other hand, models to predict transporter-mediated DDIs range from basic models to mechanistic static and dynamic models. While basic models provide conservative estimates and are useful upfront in avoiding false negative predictions, mechanistic models integrate multiple victim and perpetrator drugs parameters and are expected to provide quantitative predictions. The aim of this paper is to review the current state of the model-based approaches to predict clinical pharmacokinetics and DDIs of drugs or NMEs that are substrates of hepatic transporters.

References

  1. 1.
    Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425–46.PubMedGoogle Scholar
  2. 2.
    Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–302.PubMedGoogle Scholar
  3. 3.
    Hagenbuch B, Meier P. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003;1609(1):1–18.PubMedGoogle Scholar
  4. 4.
    Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653–65.PubMedGoogle Scholar
  5. 5.
    Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251–60.PubMedGoogle Scholar
  6. 6.
    Fahrmayr C, Fromm MF, Konig J. Hepatic OATP and OCT uptake transporters: their role for drug–drug interactions and pharmacogenetic aspects. Drug Metab Rev. 2010;42(3):380–401.PubMedGoogle Scholar
  7. 7.
    Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, et al. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica. 2011;42(1):28–45.PubMedGoogle Scholar
  8. 8.
    Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.PubMedGoogle Scholar
  9. 9.
    Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–81.PubMedGoogle Scholar
  10. 10.
    Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 2012;91(6):1053–64.PubMedGoogle Scholar
  11. 11.
    Kock K, Brouwer KL. A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther. 2012;92(5):599–612.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62(1):1–96.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Pfeifer ND, Hardwick RN, Brouwer KL. Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol. 2014;54:509–35.PubMedGoogle Scholar
  14. 14.
    Pfeifer ND, Yang K, Brouwer KL. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther. 2013;347(3):727–36.PubMedGoogle Scholar
  15. 15.
    Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008;38(7–8):778–801.PubMedGoogle Scholar
  16. 16.
    Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011;8(4):1303–13.PubMedGoogle Scholar
  17. 17.
    Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003;306(2):703–8.PubMedGoogle Scholar
  18. 18.
    Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol. 2009;296(3):C570–82.PubMedGoogle Scholar
  19. 19.
    Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, et al. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos. 2012;40(8):1527–37.PubMedGoogle Scholar
  20. 20.
    Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol. 2013;9(4):459–72.PubMedGoogle Scholar
  21. 21.
    Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.PubMedGoogle Scholar
  22. 22.
    Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–99.PubMedGoogle Scholar
  23. 23.
    Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400–7.PubMedGoogle Scholar
  25. 25.
    Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006;34(7):1247–54.PubMedGoogle Scholar
  26. 26.
    EMA. Guideline on the investigation of drug interactions. Committee for Human Medicinal Products (CHMP). London: EMA; 2012. (CPMP/EWP/560/95/Rev).Google Scholar
  27. 27.
    US FDA. Guidance for industry. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Center for Drug Evaluation and Research (CDER). Silver Spring: FDA; 2012.Google Scholar
  28. 28.
    Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45–78.PubMedGoogle Scholar
  29. 29.
    Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet. 2010;25(2):190–9.PubMedGoogle Scholar
  30. 30.
    Farmer JA. Learning from the cerivastatin experience. Lancet. 2001;358(9291):1383–5.PubMedGoogle Scholar
  31. 31.
    Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194–204.PubMedGoogle Scholar
  32. 32.
    Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25(4):2732–4.PubMedGoogle Scholar
  33. 33.
    Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75(5):455–63.PubMedGoogle Scholar
  34. 34.
    Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug–drug interactions of repaglinide. Pharm Res. 2013;30(4):1188–99.PubMedGoogle Scholar
  35. 35.
    Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575–81.PubMedGoogle Scholar
  36. 36.
    Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther. 2013;94(1):37–51.PubMedGoogle Scholar
  37. 37.
    Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004;14(7):429–40.PubMedGoogle Scholar
  38. 38.
    Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin Drug Metab Toxicol. 2012;8(6):723–43.PubMedGoogle Scholar
  39. 39.
    Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004;5(1):6–13.Google Scholar
  40. 40.
    International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–64.PubMedGoogle Scholar
  41. 41.
    Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5(7):703–29.PubMedGoogle Scholar
  42. 42.
    Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics. 2005;15(5):303–9.PubMedGoogle Scholar
  43. 43.
    Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003;73(6):554–65.PubMedGoogle Scholar
  44. 44.
    Deo AK, Prasad B, Balogh L, Lai Y, Unadkat JD. Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos. 2012;40(5):852–5.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos. 2014;42(1):78–88.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Prasad B, Lai Y, Lin Y, Unadkat JD. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci. 2013;102(3):787–93.PubMedGoogle Scholar
  47. 47.
    Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm. 2008;5(1):77–91.PubMedGoogle Scholar
  48. 48.
    Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci. 1996;85(4):411–4.PubMedGoogle Scholar
  49. 49.
    Kang HE, Lee MG. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling. Arch Pharm Res. 2011;34(11):1779–88.PubMedGoogle Scholar
  50. 50.
    Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47(9):1469–79.PubMedGoogle Scholar
  51. 51.
    Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res. 2004;21(5):785–92.PubMedGoogle Scholar
  52. 52.
    Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625–53.PubMedGoogle Scholar
  53. 53.
    Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377–90.PubMedGoogle Scholar
  54. 54.
    Roberts MS, Rowland M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm. 1986;14(3):227–60.PubMedGoogle Scholar
  55. 55.
    Fagerholm U. Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica. 2009;39(1):57–71.PubMedGoogle Scholar
  56. 56.
    Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2011;50(5):331–47.PubMedGoogle Scholar
  57. 57.
    Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.PubMedGoogle Scholar
  58. 58.
    Rowland M. Physiologically-based pharmacokinetic (PBPK) modeling and simulations principles, methods, and applications in the pharmaceutical industry. CPT Pharmacometrics Syst Pharmacol. 2013;2:e55.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Sun H, Pang KS. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res. 2010;27(7):1237–54.PubMedGoogle Scholar
  60. 60.
    De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos. 2007;35(10):1766–80.PubMedGoogle Scholar
  61. 61.
    Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos. 2005;33(1):1–9.PubMedGoogle Scholar
  62. 62.
    Yoshida K, Maeda K, Sugiyama Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug–drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol. 2013;53:581–612.PubMedGoogle Scholar
  63. 63.
    Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov. 2008;7(3):205–20.PubMedGoogle Scholar
  64. 64.
    Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215–22.PubMedGoogle Scholar
  65. 65.
    Camenisch G, Umehara K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions. Biopharm Drug Dispos. 2012;33(4):179–94.PubMedGoogle Scholar
  66. 66.
    Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40(9):1744–56.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007–17.PubMedGoogle Scholar
  68. 68.
    Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, et al. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet. 2014;53(1):73–87.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167–77.PubMedGoogle Scholar
  70. 70.
    Yamazaki M, Kobayashi K, Sugiyama Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. Biopharm Drug Dispos. 1996;17(7):607–21.PubMedGoogle Scholar
  71. 71.
    Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug–drug interactions. Pharm Res. 2012;29(10):2860–73.PubMedGoogle Scholar
  72. 72.
    Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652–62.PubMedGoogle Scholar
  73. 73.
    Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008;84(4):488–96.PubMedGoogle Scholar
  74. 74.
    Poirier A, Cascais AC, Funk C, Lave T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009;36(6):585–611.PubMedGoogle Scholar
  75. 75.
    Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94(1):64–79.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Pfeifer ND, Goss SL, Swift B, Ghibellini G, Ivanovic M, Heizer WD, et al. Effect of ritonavir on (99 m) technetium–mebrofenin disposition in humans: a semi-PBPK modeling and in vitro approach to predict transporter-mediated DDIs. CPT Pharmacometrics Syst Pharmacol. 2013;2:e20.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Poirier A, Funk C, Scherrmann JM, Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm. 2009;6(6):1716–33.PubMedGoogle Scholar
  78. 78.
    Gertz M, Tsamandouras N, Sall C, Houston JB, Galetin A. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug–drug interaction risk. Pharm Res. Epub 2014 Mar 13. doi:10.1007/s11095-014-1333-3
  79. 79.
    Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm. 2012;9(12):3535–42.PubMedGoogle Scholar
  80. 80.
    Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311(1):139–46.PubMedGoogle Scholar
  81. 81.
    Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36(10):2014–23.PubMedGoogle Scholar
  82. 82.
    Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007;35(12):2166–76.PubMedGoogle Scholar
  83. 83.
    Williamson B, Soars AC, Owen A, White P, Riley RJ, Soars MG. Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. Xenobiotica. 2013;43(10):920–31.PubMedGoogle Scholar
  84. 84.
    Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther. 1998;36(12):636–41.PubMedGoogle Scholar
  85. 85.
    Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, et al. A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J Pharmacokinet Pharmacodyn. 2014;41(3):197–209.PubMedGoogle Scholar
  86. 86.
    Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci. 2000;89(1):16–35.PubMedGoogle Scholar
  87. 87.
    Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.PubMedGoogle Scholar
  88. 88.
    Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.PubMedGoogle Scholar
  89. 89.
    Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28(1):4–18.PubMedGoogle Scholar
  90. 90.
    Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug–drug interactions. Pharm Res. 2012;29(2):411–26.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug–drug interactions. J Med Chem. 2012;55(10):4740–63.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Rowland M, Matin SB. Kinetics of drug–drug interactions. J Pharmacokinet Pharmacodyn. 1973;1(6):553–67.Google Scholar
  93. 93.
    Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, et al. Comparison of different algorithms for predicting clinical drug–drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos. 2009;37(8):1658–66.PubMedGoogle Scholar
  94. 94.
    Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther. 2006;316(1):336–48.PubMedGoogle Scholar
  95. 95.
    Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos. 2009;37(2):386–90.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug–drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil–drug interactions. Pharm Res. 2008;25(5):1063–74.PubMedGoogle Scholar
  97. 97.
    Hu ZY. Disposition pathway-dependent approach for predicting organic anion-transporting polypeptide-mediated drug–drug interactions. Clin Pharmacokinet. 2013;52(6):433–41.PubMedGoogle Scholar
  98. 98.
    Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn. 2010;37(6):575–90.PubMedGoogle Scholar
  99. 99.
    Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211–23.PubMedGoogle Scholar
  100. 100.
    Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos. 2013;41(5):966–74.PubMedGoogle Scholar
  101. 101.
    Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D. A combined model for predicting CYP3A4 clinical net drug–drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008;36(8):1698–708.PubMedGoogle Scholar
  102. 102.
    Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother. 2011;55(11):5172–7.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A. Assessment of algorithms for predicting drug–drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol. 2011;71(1):72–87.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140–8.PubMedGoogle Scholar
  105. 105.
    Peters SA, Schroeder PE, Giri N, Dolgos H. Evaluation of the use of static and dynamic models to predict drug–drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos. 2012;40(8):1495–507.PubMedGoogle Scholar
  106. 106.
    Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, et al. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug–drug interaction potential. Pharm Res. 2013;30(3):761–80.PubMedGoogle Scholar
  107. 107.
    Varma MV, Scialis RJ, Lin J, Bi YA, Rotter CJ, Goosen TC, et al. Mechanism-based pharmacokinetic modeling to evaluate transporter–enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J. 2014;16(4):736–48.PubMedGoogle Scholar
  108. 108.
    Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, et al. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos. 2013;34(8):452–61.PubMedGoogle Scholar
  109. 109.
    Amundsen R, Christensen H, Zabihyan B, Åsberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metabol Dispos. 2010;38(9):1499–504.Google Scholar
  110. 110.
    Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, et al. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res. 2008;25(8):1891–901.PubMedGoogle Scholar
  111. 111.
    Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, et al. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos. 2013;41(10):1859–66.PubMedGoogle Scholar
  112. 112.
    Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug–drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35(8):1308–14.PubMedGoogle Scholar
  113. 113.
    Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94(1):126–41.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. In vitro cytochrome P450 inhibition data and the prediction of drug–drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther. 2005;78(6):582–92.PubMedGoogle Scholar
  115. 115.
    Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev. 2012;64(6):508–14.PubMedGoogle Scholar
  116. 116.
    Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab. 2010;11(9):730–42.PubMedGoogle Scholar
  117. 117.
    Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A. Application of permeability-limited physiologically-based pharmacokinetic models: part I–digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci. 2013;102(9):3145–60.PubMedGoogle Scholar
  118. 118.
    Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009;39(6):430–43.PubMedGoogle Scholar
  119. 119.
    Chow EC, Pang KS. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab. 2013;14(1):57–79.PubMedGoogle Scholar
  120. 120.
    Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011;39(6):1031–8.PubMedGoogle Scholar
  121. 121.
    Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007;37(4):416–26.PubMedGoogle Scholar
  122. 122.
    Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73(6):538–44.PubMedGoogle Scholar
  123. 123.
    Hsu V, de LTV M, Zhao P, Zhang L, Zheng JH, Nordmark A. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet. 2014;53(3):283–93.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003;56(3):305–14.PubMedCentralPubMedGoogle Scholar
  125. 125.
    Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005;97(4):249–56.PubMedGoogle Scholar
  126. 126.
    Sall C, Houston JB, Galetin A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos. 2012;40(7):1279–89.PubMedGoogle Scholar
  127. 127.
    Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005;78(4):388–99.PubMedGoogle Scholar
  128. 128.
    Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77(6):468–78.PubMedGoogle Scholar
  129. 129.
    Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003;74(4):380–7.PubMedGoogle Scholar
  130. 130.
    Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab Dispos. 2006;34(1):191–7.PubMedGoogle Scholar
  131. 131.
    Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311(1):228–36.PubMedGoogle Scholar
  132. 132.
    Fujino H, Shimada S, Yamada I, Hirano M, Tsunenari Y, Kojima J. Studies on the interaction between fibrates and statins using human hepatic microsomes. Arzneimittelforschung. 2003;53(10):701–7.PubMedGoogle Scholar
  133. 133.
    Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46(3):347–51.PubMedGoogle Scholar
  134. 134.
    Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78–85.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78(2):154–67.PubMedGoogle Scholar
  136. 136.
    Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996;60(2):124–37.PubMedGoogle Scholar
  137. 137.
    Qiu X, Bi Y-A, Balogh LM, Lai Y. Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. J Pharm Sci. 2013;102(9):3252–63.PubMedGoogle Scholar
  138. 138.
    Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793–806.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Pfizer Worldwide Research and Development, Department of PharmacokineticsDynamics and MetabolismCambridgeUSA
  2. 2.Pfizer Worldwide Research and Development, Department of PharmacokineticsDynamics and MetabolismGrotonUSA

Personalised recommendations